TESTBANK- ҿ
Davis Advantage forPsychiatricMentalHealth Nursing Karyn
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
ҿ I. Morgan
ҿ
11thEdition
ҿ
, Table of Contents
ҿ ҿ
Chapter 01. The Concept of Stress Adaptation
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 02. Mental Health/Mental Illness: Historical and Theoretical
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Concepts
ҿ
Chapter 03. Psychopharmacology
ҿ ҿ
Chapter 04. Concepts of Psychobiology
ҿ ҿ ҿ ҿ ҿ
Chapter 05. Ethical and Legal Issues in Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 06. Cultural and Spiritual Concepts Relevant to Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 07. Relationship Development
ҿ ҿ ҿ ҿ
Chapter 08. Therapeutic Communication
ҿ ҿ ҿ
Chapter 09. The Nursing Process in Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 10. Therapeutic Groups
ҿ ҿ ҿ ҿ
Chapter 11. Intervention With Families
ҿ ҿ ҿ ҿ
Chapter 12. Milieu Therapy - The Therapeutic Community
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 13. Crisis Intervention
ҿ ҿ ҿ ҿ
Chapter 14. Assertiveness Training
ҿ ҿ ҿ
ҿChapter 15. Promoting Self-Esteem
ҿ ҿ ҿ
ҿChapter 16. Anger/Aggression
ҿ ҿ
Management Chapter 17. The Suicidal
ҿ ҿ ҿ ҿ ҿ
Client
ҿ
Chapter 18. Behavior Therapy
ҿ ҿ ҿ
Chapter 19. Cognitive Therapy
ҿ ҿ ҿ ҿ
Chapter 20. Electroconvulsive
ҿ ҿ ҿ
Therapy Chapter 21. The
ҿ ҿ ҿ ҿ
Recovery Model Chapter 22.
ҿ ҿ ҿ ҿ
Neurocognitive Disorders
ҿ ҿ
Chapter 23. Substance-Related and Addictive Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 24. Schizophrenia Spectrum and Other Psychotic Disorders
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 25. Depressive Disorders
ҿ ҿ ҿ ҿ
Chapter 26. Bipolar and Related Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 27. Anxiety, Obsessive-Compulsive, and Related Disorders Chapter
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
28: Trauma and Stressor-Related Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 29. Somatic Symptom and Dissociative Disorders
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 30. Issues Related to Human Sexuality and Gender Dysphoria
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 31. Eating Disorders
ҿ ҿ ҿ ҿ
Chapter 32. Personality Disorders
ҿ ҿ ҿ
Chapter 33. Children and Adolescents
ҿ ҿ ҿ ҿ ҿ
Chapter 34. The Aging Individual
ҿ ҿ ҿ ҿ ҿ
Chapter 35. Survivors of Abuse or Neglect
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 36. Community Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 37. The Bereaved Individual
ҿ ҿ ҿ ҿ ҿ
Chapter 38. Military Families
ҿ ҿ ҿ
,Chapter 01. Psychopharmacology ҿ ҿ
Multiple Choice ҿ
1. The NURSE manager on the psychiatric unit was explaining to the new staff the
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
differences between typical and atypical antipsychotics. The NURSE correctly states that
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
atypical antipsychotics:
ҿ ҿ
A. Remain in the system longer ҿ ҿ ҿ ҿ
B. Act more quickly to reduce delusions
ҿ ҿ ҿ ҿ ҿ
C. Produce fewer extrapyramidal effects ҿ ҿ ҿ
D. Are risk free for neuroleptic malignant syndrome (NMS)
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
CORRECT qANSWER:C ҿ
Atypical antipsychotics produce less D2blockade; thus movement disorders are less of a problem. No
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
evidence suggests that the medication remains in the system longer nor that it acts more quicklyto reduce
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
delusions. The atypicals are not risk free for NMS.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Implementation | Client
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
ҿNeed:
Physiological Integrity: Pharmacological and Parenteral Therapies ҿ ҿ ҿ ҿ ҿ
2. The NURSE would assess for neuroleptic malignant syndrome (NMS) if a patient
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
on haloperidol (Haldol) develops a:
ҿ ҿ ҿ ҿ ҿ
A. 30 mm Hg decrease in blood pressure reading
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
B. Respiratory rate of 24 respirations per minute ҿ ҿ ҿ ҿ ҿ ҿ
C. Temperature reading of 104° F ҿ ҿ ҿ ҿ
D. Pulse rate of 70 beats per minute
ҿ ҿ ҿ ҿ ҿ ҿ
CORRECT qANSWER:C ҿ
Increased temperature is the cardinal sign of NMS. This BP is not a significant feature of NMS. There
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
are no significant findings to support the options related to respirations or pulse rate.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Assessment | Client Need:
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Physiological Integrity: Pharmacological and Parenteral Therapies ҿ ҿ ҿ ҿ ҿ
3. A patient taking fluphenazine (Prolixin) complains of dry mouth and blurred vision. What would
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
the NURSE assess as the likely cause of these symptoms?
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
A. Decreased dopamine at receptor sites ҿ ҿ ҿ ҿ
B. Blockade of histamine ҿ ҿ
C. Cholinergic blockade ҿ
D. Adrenergic blocking ҿ
CORRECT qANSWER:C ҿ
Fluphenazine administration produces blockade of cholinergic receptors giving rise to anticholinergic
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
effects, such as dry mouth, blurred vision, and constipation.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
, KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Assessment | Client Need:
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Davis Advantage forPsychiatricMentalHealth Nursing Karyn
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
ҿ I. Morgan
ҿ
11thEdition
ҿ
, Table of Contents
ҿ ҿ
Chapter 01. The Concept of Stress Adaptation
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 02. Mental Health/Mental Illness: Historical and Theoretical
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Concepts
ҿ
Chapter 03. Psychopharmacology
ҿ ҿ
Chapter 04. Concepts of Psychobiology
ҿ ҿ ҿ ҿ ҿ
Chapter 05. Ethical and Legal Issues in Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 06. Cultural and Spiritual Concepts Relevant to Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 07. Relationship Development
ҿ ҿ ҿ ҿ
Chapter 08. Therapeutic Communication
ҿ ҿ ҿ
Chapter 09. The Nursing Process in Psychiatric/Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 10. Therapeutic Groups
ҿ ҿ ҿ ҿ
Chapter 11. Intervention With Families
ҿ ҿ ҿ ҿ
Chapter 12. Milieu Therapy - The Therapeutic Community
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 13. Crisis Intervention
ҿ ҿ ҿ ҿ
Chapter 14. Assertiveness Training
ҿ ҿ ҿ
ҿChapter 15. Promoting Self-Esteem
ҿ ҿ ҿ
ҿChapter 16. Anger/Aggression
ҿ ҿ
Management Chapter 17. The Suicidal
ҿ ҿ ҿ ҿ ҿ
Client
ҿ
Chapter 18. Behavior Therapy
ҿ ҿ ҿ
Chapter 19. Cognitive Therapy
ҿ ҿ ҿ ҿ
Chapter 20. Electroconvulsive
ҿ ҿ ҿ
Therapy Chapter 21. The
ҿ ҿ ҿ ҿ
Recovery Model Chapter 22.
ҿ ҿ ҿ ҿ
Neurocognitive Disorders
ҿ ҿ
Chapter 23. Substance-Related and Addictive Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 24. Schizophrenia Spectrum and Other Psychotic Disorders
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 25. Depressive Disorders
ҿ ҿ ҿ ҿ
Chapter 26. Bipolar and Related Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 27. Anxiety, Obsessive-Compulsive, and Related Disorders Chapter
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
28: Trauma and Stressor-Related Disorders
ҿ ҿ ҿ ҿ ҿ
Chapter 29. Somatic Symptom and Dissociative Disorders
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 30. Issues Related to Human Sexuality and Gender Dysphoria
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 31. Eating Disorders
ҿ ҿ ҿ ҿ
Chapter 32. Personality Disorders
ҿ ҿ ҿ
Chapter 33. Children and Adolescents
ҿ ҿ ҿ ҿ ҿ
Chapter 34. The Aging Individual
ҿ ҿ ҿ ҿ ҿ
Chapter 35. Survivors of Abuse or Neglect
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 36. Community Mental Health Nursing
ҿ ҿ ҿ ҿ ҿ ҿ
Chapter 37. The Bereaved Individual
ҿ ҿ ҿ ҿ ҿ
Chapter 38. Military Families
ҿ ҿ ҿ
,Chapter 01. Psychopharmacology ҿ ҿ
Multiple Choice ҿ
1. The NURSE manager on the psychiatric unit was explaining to the new staff the
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
differences between typical and atypical antipsychotics. The NURSE correctly states that
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
atypical antipsychotics:
ҿ ҿ
A. Remain in the system longer ҿ ҿ ҿ ҿ
B. Act more quickly to reduce delusions
ҿ ҿ ҿ ҿ ҿ
C. Produce fewer extrapyramidal effects ҿ ҿ ҿ
D. Are risk free for neuroleptic malignant syndrome (NMS)
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
CORRECT qANSWER:C ҿ
Atypical antipsychotics produce less D2blockade; thus movement disorders are less of a problem. No
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
evidence suggests that the medication remains in the system longer nor that it acts more quicklyto reduce
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
delusions. The atypicals are not risk free for NMS.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Implementation | Client
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
ҿNeed:
Physiological Integrity: Pharmacological and Parenteral Therapies ҿ ҿ ҿ ҿ ҿ
2. The NURSE would assess for neuroleptic malignant syndrome (NMS) if a patient
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
on haloperidol (Haldol) develops a:
ҿ ҿ ҿ ҿ ҿ
A. 30 mm Hg decrease in blood pressure reading
ҿ ҿ ҿ ҿ ҿ ҿ ҿ
B. Respiratory rate of 24 respirations per minute ҿ ҿ ҿ ҿ ҿ ҿ
C. Temperature reading of 104° F ҿ ҿ ҿ ҿ
D. Pulse rate of 70 beats per minute
ҿ ҿ ҿ ҿ ҿ ҿ
CORRECT qANSWER:C ҿ
Increased temperature is the cardinal sign of NMS. This BP is not a significant feature of NMS. There
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
are no significant findings to support the options related to respirations or pulse rate.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Assessment | Client Need:
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
Physiological Integrity: Pharmacological and Parenteral Therapies ҿ ҿ ҿ ҿ ҿ
3. A patient taking fluphenazine (Prolixin) complains of dry mouth and blurred vision. What would
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
the NURSE assess as the likely cause of these symptoms?
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
A. Decreased dopamine at receptor sites ҿ ҿ ҿ ҿ
B. Blockade of histamine ҿ ҿ
C. Cholinergic blockade ҿ
D. Adrenergic blocking ҿ
CORRECT qANSWER:C ҿ
Fluphenazine administration produces blockade of cholinergic receptors giving rise to anticholinergic
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
effects, such as dry mouth, blurred vision, and constipation.
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
, KEY: Cognitive Level: Application | Integrated Processes: Nursing Process: Assessment | Client Need:
ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ ҿ
